Cargando…
Does cancer deserve special treatment when health technologies are prioritized?
Despite most new cancer treatments having relatively high costs and low health benefits, they are often funded ahead of treatments for other illnesses. And yet, according to the article by Dan Greenberg and colleagues, most Israeli oncologists and family physicians think that new cancer treatments s...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843515/ https://www.ncbi.nlm.nih.gov/pubmed/24245831 http://dx.doi.org/10.1186/2045-4015-2-45 |
_version_ | 1782293057106870272 |
---|---|
author | Hansen, Paul |
author_facet | Hansen, Paul |
author_sort | Hansen, Paul |
collection | PubMed |
description | Despite most new cancer treatments having relatively high costs and low health benefits, they are often funded ahead of treatments for other illnesses. And yet, according to the article by Dan Greenberg and colleagues, most Israeli oncologists and family physicians think that new cancer treatments should not receive such a high priority and that cost-effectiveness data should be used to support funding decisions. In this commentary, I point out that the increasing pressure worldwide when prioritizing health technologies to widen the scope of the benefits that are recognized beyond just narrowly-defined health benefits would almost certainly include the special characteristics of cancer. Future research would be worthwhile into how the criteria for prioritizing technologies should be incorporated into prioritization frameworks in practice, including, in particular, how to resolve the inherent trade-offs. This is a commentary on http://www.ijhpr.org/content/2/2/44/ |
format | Online Article Text |
id | pubmed-3843515 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-38435152013-11-30 Does cancer deserve special treatment when health technologies are prioritized? Hansen, Paul Isr J Health Policy Res Commentary Despite most new cancer treatments having relatively high costs and low health benefits, they are often funded ahead of treatments for other illnesses. And yet, according to the article by Dan Greenberg and colleagues, most Israeli oncologists and family physicians think that new cancer treatments should not receive such a high priority and that cost-effectiveness data should be used to support funding decisions. In this commentary, I point out that the increasing pressure worldwide when prioritizing health technologies to widen the scope of the benefits that are recognized beyond just narrowly-defined health benefits would almost certainly include the special characteristics of cancer. Future research would be worthwhile into how the criteria for prioritizing technologies should be incorporated into prioritization frameworks in practice, including, in particular, how to resolve the inherent trade-offs. This is a commentary on http://www.ijhpr.org/content/2/2/44/ BioMed Central 2013-11-18 /pmc/articles/PMC3843515/ /pubmed/24245831 http://dx.doi.org/10.1186/2045-4015-2-45 Text en Copyright © 2013 Hansen; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Commentary Hansen, Paul Does cancer deserve special treatment when health technologies are prioritized? |
title | Does cancer deserve special treatment when health technologies are prioritized? |
title_full | Does cancer deserve special treatment when health technologies are prioritized? |
title_fullStr | Does cancer deserve special treatment when health technologies are prioritized? |
title_full_unstemmed | Does cancer deserve special treatment when health technologies are prioritized? |
title_short | Does cancer deserve special treatment when health technologies are prioritized? |
title_sort | does cancer deserve special treatment when health technologies are prioritized? |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843515/ https://www.ncbi.nlm.nih.gov/pubmed/24245831 http://dx.doi.org/10.1186/2045-4015-2-45 |
work_keys_str_mv | AT hansenpaul doescancerdeservespecialtreatmentwhenhealthtechnologiesareprioritized |